I'm on mobile at the moment. Anyone know how many instruments it would be from ~$1m? It's quite important as labs that now have the instrument are more likely to stay with easyscreen reagents for the foreseeable future - more sales of respiratory, STI, enteric, flavavirus panels etc..If allall $11m of revenue fell within the Q4, SP would've shot up well past $3. Regardless good times ahead
Ann: Quarterly report and Appendix 4C, page-10
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add GSS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
69.0¢ |
Change
0.010(1.47%) |
Mkt cap ! $154.2M | |||
| Open | High | Low | Value | Volume |
| 68.0¢ | 69.0¢ | 68.0¢ | $15.17K | 22.30K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8809 | 68.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 69.0¢ | 3668 | 1 |
View Market Depth
| Last trade - 11.36am 07/11/2024 (20 minute delay) ? |
| GSS (ASX) Chart |